title: Recombinant vaccinia viruses which express MHV-JHM proteins: protective immune response and the influence of vaccination on coronavirus-induced encephalomyelitis.
abstract: Vaccinia-virus (VV) recombinants encoding either the nucleocapsid (N) or the spike (S) protein of MHV-JHM were constructed to study the role of the immune response against defined coronavirus antigens. For the S-protein, a fusogenic (Sfus+) or non fusogenic variant (Sfus-) of the gene was inserted into the VV genome. A strong protection against acute encephalomyelitis (AE) was mediated in Lewis rats which were immunized by VV-Sfus+ and challenged with an otherwise lethal dose of MHV-JHM before the induction of S-specific IgG antibodies. By contrast, a VV recombinant encoding a variant non fusogenic S-protein or the N-protein was not capable conferring protection. In addition, we demonstrated that MHV-JHM S-specific IgG antibodies elicited before MHV-JHM challenge modulated the disease process, changing it from an acute disease to subacute demyelinating encephalomyelitis (SDE).
authors.affiliation: Institute of Virology and Immunobiology, Würzburg, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Flory
authors.forename: A
authors.initials: A
authors.lastname: Stühler
authors.forename: H
authors.initials: H
authors.lastname: Wege
authors.forename: S
authors.initials: S
authors.lastname: Siddell
authors.forename: H
authors.initials: H
authors.lastname: Wege
mesh_terms: D000208:Acute Disease; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D002213:Capsid / Q000276:immunology*; D002459:Cell Fusion; D002908:Chronic Disease; D003711:Demyelinating Diseases / Q000209:etiology* / Q000276:immunology; D004679:Encephalomyelitis / Q000276:immunology / Q000517:prevention & control*; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000276:immunology; D008562:Membrane Glycoproteins / Q000235:genetics / Q000276:immunology*; D006517:Murine hepatitis virus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity / Q000502:physiology; D051381:Rats; D011917:Rats, Inbred Lew; D011995:Recombination, Genetic; D064370:Spike Glycoprotein, Coronavirus; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014611:Vaccination / Q000009:adverse effects; D014614:Vaccines, Synthetic / Q000276:immunology / Q000633:toxicity; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology*; D014758:Viral Core Proteins / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology / Q000633:toxicity; D014774:Virulence; D017735:Virus Latency
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D008562:Membrane Glycoproteins; D064370:Spike Glycoprotein, Coronavirus; D014614:Vaccines, Synthetic; D014758:Viral Core Proteins; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C578557:spike glycoprotein, SARS-CoV; C578553:spike protein, mouse hepatitis virus